Earth Science Tech, Inc. (ETST) Has Team in Place
Post# of 333
(Total Views: 230)
Posted On: 04/18/2018 6:20:43 PM
Earth Science Tech, Inc. (ETST) Has Team in Place to Become Licensed Distributor of Controlled Substances in Canada
- Jad Nammour joins the company as new Chief of Pharmacy, bringing over 20 years of experience to ETST
- Positioned for sales growth with a strong, completed team of industry professionals
- Accelerating the development and commercialization of new products in Canada and overseas
Earth Science Tech, Inc. (OTC: ETST), a Florida-based biotech company focused on cannabis and cannabinoid research and development, nutraceuticals and pharmaceuticals, as well as on R&D for certain medical devices, recently announced Jad Nammour as its new Chief of Pharmacy (http://nnw.fm/8fuO5). Nammour is trained to develop master formulae, the templates for mass production of non-sterile medicinal products. Having a certified pharmacist on staff is required by law to obtain a license to distribute controlled substances. Nammour fills this final important technical gap in the production and development teams. His job will be to make sure that controlled substances and drugs are managed, handled and stored correctly. He will also help in the development and marketing of the company’s nutraceutical patents, pharmacological products and medical devices. The adding of the new Chief of Pharmacy brings ETST one step closer to obtaining a final license to distribute controlled substances, and completes the management and development teams.
ETST has positioned itself for growth in 2018 through the addition of its new COO, Gagan Hunter, in March (http://nnw.fm/aFs7q) and the final addition of new Chief of Pharmacy Jad Nammour in April. In a news release, Dr. Michel Aube, CEO & CSO, stated “We have all of the knowledge, experience and proficiency that we need to bring our products to the marketplace and become a licensed distributor of drugs and controlled substances in Canada, as announced earlier this year.” The company holds three wholly owned subsidiaries: Earth Science Pharmaceutical, Cannabis Therapeutics, and KannaBidioiD. In addition, Canadian subsidiary Canna Inno Laboratories Inc. was formed by ETST in 2017, as a strategic Montreal, Canada-based company, to give ETST a foothold in Québec, providing the company with access to government grants.
The company has already received a grant through Canna Inno Laboratories Inc. from the Government of Québec to support the pre-launch process of three CBD-based products that aim to prevent common causes of cancer and help reduce occurrence rates. ETST is strategically working to improve treatments for different diseases on a global scale. Human clinical trials are set to begin in 2019, or later, in producing an over-the-counter (OTC) drug and a cannabinoid companion generic drug that battles opioid dependency. ETST is planning to investigate the synergies between mineral elements and cannabinoid industrial hemp oil. This could potentially be used as a treatment for opioid dependency. In March 2018, ETST announced its membership in the largest innovative business acceleration program in Québec (http://nnw.fm/VP4cn). With this membership, the company is poised to accelerate the development and commercialization of new products in Canada and overseas.
For more information, visit the company’s website at www.EarthScienceTech.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Jad Nammour joins the company as new Chief of Pharmacy, bringing over 20 years of experience to ETST
- Positioned for sales growth with a strong, completed team of industry professionals
- Accelerating the development and commercialization of new products in Canada and overseas
Earth Science Tech, Inc. (OTC: ETST), a Florida-based biotech company focused on cannabis and cannabinoid research and development, nutraceuticals and pharmaceuticals, as well as on R&D for certain medical devices, recently announced Jad Nammour as its new Chief of Pharmacy (http://nnw.fm/8fuO5). Nammour is trained to develop master formulae, the templates for mass production of non-sterile medicinal products. Having a certified pharmacist on staff is required by law to obtain a license to distribute controlled substances. Nammour fills this final important technical gap in the production and development teams. His job will be to make sure that controlled substances and drugs are managed, handled and stored correctly. He will also help in the development and marketing of the company’s nutraceutical patents, pharmacological products and medical devices. The adding of the new Chief of Pharmacy brings ETST one step closer to obtaining a final license to distribute controlled substances, and completes the management and development teams.
ETST has positioned itself for growth in 2018 through the addition of its new COO, Gagan Hunter, in March (http://nnw.fm/aFs7q) and the final addition of new Chief of Pharmacy Jad Nammour in April. In a news release, Dr. Michel Aube, CEO & CSO, stated “We have all of the knowledge, experience and proficiency that we need to bring our products to the marketplace and become a licensed distributor of drugs and controlled substances in Canada, as announced earlier this year.” The company holds three wholly owned subsidiaries: Earth Science Pharmaceutical, Cannabis Therapeutics, and KannaBidioiD. In addition, Canadian subsidiary Canna Inno Laboratories Inc. was formed by ETST in 2017, as a strategic Montreal, Canada-based company, to give ETST a foothold in Québec, providing the company with access to government grants.
The company has already received a grant through Canna Inno Laboratories Inc. from the Government of Québec to support the pre-launch process of three CBD-based products that aim to prevent common causes of cancer and help reduce occurrence rates. ETST is strategically working to improve treatments for different diseases on a global scale. Human clinical trials are set to begin in 2019, or later, in producing an over-the-counter (OTC) drug and a cannabinoid companion generic drug that battles opioid dependency. ETST is planning to investigate the synergies between mineral elements and cannabinoid industrial hemp oil. This could potentially be used as a treatment for opioid dependency. In March 2018, ETST announced its membership in the largest innovative business acceleration program in Québec (http://nnw.fm/VP4cn). With this membership, the company is poised to accelerate the development and commercialization of new products in Canada and overseas.
For more information, visit the company’s website at www.EarthScienceTech.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)